Pfizer Limited will discontinue the marketing, distribution and sale of Minipress XL effective September 7, 2026. The move follows a decision by Pfizer Inc. USA to halt manufacturing of the product.

Key details of the development

The transaction involves Pfizer Limited exiting the Minipress XL product line and receiving a corresponding payment from its US parent entity. The details of this corporate development are summarised below.

Minipress XL is a product that Pfizer Limited will cease to sell as part of this arrangement. The discontinuation is consequent to the decision by Pfizer Inc. USA to discontinue the manufacture of Minipress XL.

In connection with the above, the company will receive a lump sum payment of $13.9 million, equivalent to about ₹131.38 crore, from Pfizer Inc. USA. This payment compensates for the exit from the specific product line.

Representative Carol Miller sold shares of Pfizer valued between $60,004 and $200,000. The transaction took place on March 10, 2025, according to a filing published on August 13, 2026.

At the time of reporting, Pfizer shares were trading at $26.61, down 0.69%.

Recent Trading Activity

Over the past three years, Miller executed 35 trades totaling over $238,000. Her largest trades involved Comcast and McKesson stock.

Regulatory Context

Under the STOCK Act signed into law in April 2012, members of Congress must file a Periodic Transaction Report within 30 days of notification and within 45 days of the transaction date. The act prohibits using private information for personal gain.

What the Numbers Show

The sale represents a significant portion of Miller’s recent trading activity. With 35 trades totaling $238,000 over three years, the Pfizer sale falls within the upper range of her disclosed transaction values, though specific per-trade averages are not provided in the source.